<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00264212</url>
  </required_header>
  <id_info>
    <org_study_id>R_8791</org_study_id>
    <nct_id>NCT00264212</nct_id>
  </id_info>
  <brief_title>AMISH : Aprovel for Management of Isolated Systolic Hypertension</brief_title>
  <official_title>A Multicentre Prospective Randomized Open-Label 12-Week Study With Blinded Evaluation Comparing the Efficacy and Safety of Irbesartan and Irbesartan-Hydrochlorothiazide Fixed Combination With Amlodipine and Amlodipine Plus Hydrochlorothiazide in Elderly Patients With Isolated Systolic Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To compare the antihypertensive efficacy and tolerability of irbesartan and
      irbesartan-hydrochlorothiazide fixed combination therapy with amlodipine and amlodipine plus
      hydrochlorothiazide in the treatment of isolated systolic hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in office seated SBP at week 12</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>At 4, 8 and 12 weeks: Number of responders and normalized, Change from baseline in pulse pressure (SBP-DBP), Change from baseline in standing SBP, Safety : Change in standing SBP/DBP, incidence of orthostatic hypotension, adverse events</measure>
  </secondary_outcome>
  <enrollment>436</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irbesartan and irbesartan-hydrochlorothiazide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main criteria are listed hereafter:

        Inclusion Criteria:

          -  at Screening

               -  Outpatients

               -  With newly diagnosed and untreated OR previously diagnosed, treated and
                  uncontrolled Isolated Systolic Hypertension defined as:

                    -  seated Systolic Blood Pressure (SBP) ≥ 160mmHg and &lt; 220 mmHg [160-220[

                    -  AND seated Diastolic Blood Pressure (DBP)&lt; 90 mmHg

          -  at Randomization

               -  Having completed the 2 to 4-week wash-out/placebo run-in phase

               -  Still eligible for Blood Pressure

               -  seated SBP ≥ 160mmHg and &lt; 220 mmHg [160-220[

               -  AND seated DBP &lt; 90 mmHg.

        Exclusion Criteria (at Screening):

          -  Participation in a clinical trial within the previous 3 months

          -  Patients with a history of irbesartan, amlodipine, or hydrochlorothiazide sensitivity
             defined as irbesartan, amlodipine, or hydrochlorothiazide discontinuation due to
             medically significant adverse effects

          -  Patients currently or previously treated with Angiotensin II Receptor Blocker
             (irbesartan, losartan, candesartan, valsartan, telmisartan, etc.) or dihydropiridine
             Calcium Channel Blocker (amlodipine, nicardipine, felodipine, nifedipine, etc.) AND
             not responding despite maximum tolerated dose

          -  Known or suspected secondary hypertension (e.g., coarctation of aorta, renovascular
             stenosis, etc.)

          -  Known single functional kidney

          -  History of recent myocardial infarction, coronary artery bypass graft surgery or
             percutaneous transluminal coronary angioplasty, or cerebrovascular accident (Transient
             Ischaemic Attack, stroke) within the last 6 months of study entry

          -  Patients with known gastrointestinal, renal, hepatic, endocrine, cardiovascular,
             pulmonary, immunological or hematological disease which in the opinion of the
             investigator is active or uncontrolled

          -  Patients with significant renal (clearance of creatinine &lt; 30 mL/mn), hepatic or
             cardiac insufficiency, or known valvular heart disease

          -  Serum potassium &lt; 3.5 mmol/L (mEq/L) or &gt; 5.5 mmol/L (mEq/L)

          -  Presence of clinically significant ventricular or supraventricular arrhythmias, or
             second or third degree atrioventricular block, or QTc prolongation (Bazett &gt; 450
             msec.) on the ECG

          -  Pregnancy or lactation. Women of child bearing potential (not post-menopausal) should
             be using a reliable contraceptive method

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascale BLONDIN, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Shangai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>China</country>
    <country>Indonesia</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2005</study_first_submitted>
  <study_first_submitted_qc>December 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2005</study_first_posted>
  <last_update_submitted>December 17, 2007</last_update_submitted>
  <last_update_submitted_qc>December 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

